Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Immunol Res ; 65(1): 157-163, 2017 02.
Article in English | MEDLINE | ID: mdl-27435706

ABSTRACT

Autoimmune reaction after vaccination is sporadically reported in the medical literature. Vaccinations are generally safe and have an important role in eradicating endemic diseases worldwide. Nevertheless, the question arises as to whether there is a possibility of post-vaccination autoimmune phenomena. The anti-tetanus vaccine is being used since 1924, and it is part of the recommended immunization schedules for children. There are few reports of autoimmune diseases, such as rheumatoid arthritis and anti-phospholipid syndrome after anti-tetanus vaccination. Herein, we describe four cases, of which we believe, show a clear temporal relation between anti-tetanus vaccination and the appearance of dermatomyositis, systemic lupus erythematosus, type 1 diabetes mellitus and anti-phospholipid syndrome. We also suggest some of the pathogenic mechanisms that promote a pathogenic autoimmune response.


Subject(s)
Autoimmune Diseases/etiology , Tetanus Toxoid/adverse effects , Adolescent , Adult , Autoimmunity , Female , Humans , Male , Middle Aged , Vaccination/adverse effects
2.
Int J Clin Pract ; 64(10): 1398-401, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20716147

ABSTRACT

INTRODUCTION: Hypothalamic-pituitary-adrenal (HPA) axis insufficiency is the most common endocrine disorder in patients with antiphospholipid syndrome (APS). Primary adrenal failure because of venous thrombosis and/or adrenal haemorrhage is the leading diagnosis, while another possible mechanism is autoimmune adrenal failure. Prospective evaluation of the HPA axis in patients with APS has not been previously performed. AIMS: To evaluate the HPA axis in patients with APS. METHODS: Ambulatory patients (age 18 years and older) with APS were given a symptom questionnaire. Baseline aldosterone, corticotropin (ACTH) and adrenal cortex autoantibodies (ACA) were measured. Cortisol was measured at baseline and after 1-mcg ACTH stimulation. RESULTS: In all, 24 patients (18 women/6 men; mean age 44.6 +/- 16.1 years) participated in the study. Of these, 21 had primary APS with disease duration of 5.8 +/- 6.2 years. Baseline cortisol level was 12.6 +/- 4.2 mg/dl (normal 7-25). After ACTH stimulation, it was 24.7 +/- 4.1 mg/dl and 22.8 +/- 7.4 mg/dl at 30 and 60 min respectively. All patients had a stimulated cortisol level of at least 18 mg/dl, although three patients had stimulated cortisol between 18 and 20 mg/dl, one of which reported previous inhaled steroid treatment. Weakness, dizziness and nausea were reported at baseline by 50%, 38% and 25% of the patients respectively. ACA were negative in all patients examined. CONCLUSIONS: In our cohort, patients with APS did not have HPA axis insufficiency. Partial adrenal insufficiency could not be excluded in two patients. Further longitudinal studies are needed to determine the significance of periodic evaluation of the HPA axis in patients with APS.


Subject(s)
Antiphospholipid Syndrome/complications , Hypothalamic Diseases/etiology , Hypothalamo-Hypophyseal System/physiology , Pituitary-Adrenal System/physiology , Adrenocorticotropic Hormone/metabolism , Adult , Aged , Antiphospholipid Syndrome/physiopathology , Blood Glucose/metabolism , Female , Hormones , Humans , Hydrocortisone/metabolism , Hypothalamic Diseases/physiopathology , Male , Middle Aged , Young Adult
3.
Lupus ; 18(13): 1226-32, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19880573

ABSTRACT

Since the early 1980s, case reports and case series describe an association between silicon breast implants and the appearance of autoimmune diseases, particularly scleroderma. The publication of those cases led to a large number of studies to investigate this association. The conclusion of those studies is that most probably there has not been an increased incidence of autoimmune diseases in women with silicon breast implants. Nevertheless, the US Food and Drug Administration determined that silicone gel breast implants are not completely safe, only that they are 'reasonably safe.' The debate continues regarding this association. In this article we present new cases of silicon breast implant-induced scleroderma and review the literature on this subject.


Subject(s)
Autoimmune Diseases/etiology , Breast Implants/adverse effects , Scleroderma, Systemic/etiology , Silicone Gels/adverse effects , Adult , Aged , Autoantibodies/blood , Autoantibodies/immunology , Autoimmune Diseases/immunology , Breast Implantation/adverse effects , Female , Humans , Middle Aged , Scleroderma, Systemic/immunology , United States , United States Food and Drug Administration
4.
QJM ; 101(11): 871-4, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18772151

ABSTRACT

BACKGROUND: Thyrotoxicosis is often diagnosed in an outpatient setting. The most common symptoms include irritability, heat intolerance, palpitations and weakness. Sometimes, however, thyrotoxicosis is first diagnosed in the hospital setting. The prevalent symptoms in hospitalized patients with newly diagnosed thyrotoxicosis have not been fully characterized. AIM: To determine the clinical characteristics of patients with thyrotoxicosis newly diagnosed during hospitalization. DESIGN: A retrospective computer-based search was undertaken to detect patients that were hospitalized in our medical centre during 1999-2006, and discharged with thyrotoxicosis or thyroiditis as the primary diagnosis. RESULTS: Fifty-eight patients (36F/22M; mean age 52.1 +/- 17.5 years) were identified. Weakness, weight loss and palpitations were the most common manifestations (50, 40 and 35%, respectively) and were predominantly present in patients with hyperthyroidism. Sore throat was present in 41% of patients with thyroiditis. Sinus tachycardia and atrial fibrillation occurred in 65.5 and 15.5% of the patients, more common in those with hyperthyroidism. The diagnoses on discharge were Graves' disease, subacute thyroiditis and multinodular goiter in 39.7, 34.5 and 8.9%, respectively. CONCLUSION: Weakness, weight loss and palpitations were the main symptoms in patients diagnosed with thyrotoxicosis during hospitalization. Thyrotoxicosis should be included in the differential diagnosis when patients are admitted to the hospital with those symptoms.


Subject(s)
Hospitalization , Thyrotoxicosis/diagnosis , Adult , Aged , Aged, 80 and over , Chi-Square Distribution , Female , Humans , Hyperthyroidism/complications , Hyperthyroidism/epidemiology , Male , Middle Aged , Retrospective Studies , Thyroiditis/complications , Thyroiditis/epidemiology , Thyrotoxicosis/epidemiology , Thyrotoxicosis/etiology , Young Adult
5.
J Clin Endocrinol Metab ; 86(11): 5142-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11701667

ABSTRACT

Resistance to thyroid hormone (RTH) is a syndrome in which patients have elevated thyroid hormone (TH) levels and decreased sensitivity to its action. We describe a child with extreme RTH and a severe phenotype. A 22-month-old female presented to the NIH with goiter, growth retardation, short stature, and deafness. Additionally, the patient had hypotonia, mental retardation, visual impairment, and a history of seizures. Brain magnetic resonance imaging showed evidence of demyelination and bilateral ventricular enlargement. The patient had markedly elevated free T3 and free T4 levels of more than 2000 pg/dl (normal, 230-420 pg/dl) and more than 64 pmol/liter (normal, 10.3-20.6 pmol/liter), respectively, and TSH of 6.88 mU/liter (normal, 0.6-6.3 mU/liter). These are the highest TH levels reported for a heterozygous RTH patient. A T3 stimulation test confirmed the diagnosis of RTH in the pituitary and peripheral tissues. Molecular analyses of the patient's genomic DNA by PCR identified a single base deletion in exon 10 of her TRbeta gene that resulted in a frameshift and early stop codon. This, in turn, encoded a truncated receptor that lacked the last 20 amino acids. Cotransfection studies showed that the mutant TR was transcriptionally inactive even in the presence of 10(-6) M T3 and had strong dominant negative activity over the wild-type receptor. It is likely that the severely defective TRbeta mutant contributed to the extreme RTH phenotype and resistance in our patient.


Subject(s)
Thyroid Hormone Resistance Syndrome/genetics , Bone Development/physiology , Brain/pathology , Cells, Cultured , Female , Frameshift Mutation , Gene Deletion , Humans , Infant , Magnetic Resonance Imaging , Phenotype , Thyroxine/blood , Transcription, Genetic/genetics , Transfection , Triiodothyronine/blood
6.
Ann Pharmacother ; 35(12): 1578-83, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11793625

ABSTRACT

OBJECTIVE: To describe a patient with primary hypothyroidism in whom ingestion of levothyroxine with calcium carbonate led to markedly elevated serum thyrotropin concentrations. CASE SUMMARY: A 61-year-old white woman with primary hypothyroidism, systemic lupus erythematosus, celiac disease, and history of Whipple resection for pancreatic cancer was euthyroid with levothyroxine 175-188 micrograms/d. After taking a high dose of calcium carbonate (1250 mg three times daily) with levothyroxine, she developed biochemical evidence of hypothyroidism (thyrotropin up to 41.4 mU/L) while remaining clinically euthyroid. Delaying calcium carbonate administration by four hours returned her serum thyrotropin to a borderline high concentration (5.7 mU/L) within a month. Serum concentrations of unbound and total thyroxine and triiodothyronine tended to decrease, but remained borderline low to normal while the patient concomitantly received levothyroxine and calcium carbonate. DISCUSSION: Concomitant administration of levothyroxine and calcium carbonate often results in levothyroxine malabsorption. While in most patients the clinical consequences of this interaction, even with prolonged exposure, are relatively small, overt hypothyrodism may develop in patients with preexisting malabsorption disorders. However, as the current case illustrates, the clinical manifestations of the initial levothyroxine deficit may not always be apparent and, of all usual laboratory thyroid function tests, only thyrotropin measurement will reliably uncover the exaggerated levothyroxine malabsorption. CONCLUSIONS: Decreased absorption of levothyroxine when given with calcium carbonate may be particularly pronounced in patients with preexisting malabsorption disorders. Once recognized, a change in drug administration schedule usually minimizes or eliminates this interaction.


Subject(s)
Antacids/adverse effects , Calcium Carbonate/adverse effects , Hypothyroidism/drug therapy , Malabsorption Syndromes/chemically induced , Thyroxine/therapeutic use , Celiac Disease/complications , Female , Humans , Hypothyroidism/complications , Intestinal Absorption/drug effects , Lupus Erythematosus, Systemic/complications , Middle Aged , Thyrotropin/blood , Thyroxine/metabolism
7.
J Clin Endocrinol Metab ; 85(1): 237-44, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10634393

ABSTRACT

The optimal treatment of metastatic thyroid cancer that produces high amounts of thyroid hormone has not been well defined. A 46-yr-old woman presented with a follicular thyroid carcinoma arising from a struma ovarii with hepatic metastases. After the removal of both the struma and the thyroid gland, the liver metastases showed evidence of a high degree of hormonogenesis. Brain, chest, abdomen, and bone imaging was negative for additional metastases. Because iodine uptake by most thyroid carcinomas is quite low in the absence of high levels of ambient TSH, we used recombinant human TSH (rhTSH) (Thyrogen) to achieve a concentration of 131I activity in the tumor high enough for a significant cytotoxic effect. After rhTSH administration (0.9 mg im daily for 2 consecutive days), a 131I diagnostic whole body scan confirmed the existence of 17 discrete hepatic foci of 131I uptake. To calculate the amount of 131I that would deliver an absorbed radiation dose that would be optimally cytotoxic to the metastases (>8000 rad/lesion) and not to the normal liver, we performed lesion dosimetry. Analysis of dosimetric data showed that 15 of 17 lesions would receive an adequate radiation dose following the administration of 65 mCi of 131I. Additionally, we performed whole body dosimetry to assure that this dose would not cause bone marrow toxicity. The patient was reevaluated 6 months after therapy; the liver metastases showed significant, but partial, response. In conclusion, we used the combination of rhTSH with lesional and whole body dosimetry for the treatment of highly functional metastases from follicular thyroid carcinoma arising within a struma ovarii. This strategy can be applied to determine a safe and effective dose of 131I for the treatment of any thyroid cancer metastases that produce enough TH to preclude stimulation of endogenous pituitary TSH secretion.


Subject(s)
Ovarian Neoplasms/secondary , Struma Ovarii/secondary , Teratoma/pathology , Thyroid Neoplasms/pathology , Thyrotropin/therapeutic use , Female , Humans , Iodine Radioisotopes/therapeutic use , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Magnetic Resonance Imaging , Middle Aged , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/radiotherapy , Recombinant Proteins/therapeutic use , Struma Ovarii/diagnosis , Struma Ovarii/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...